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Recommended by David Spooner
Despite the clinical and ﬁnancial implications, there is little evidence about how patients who have been treated for soft tis-
sue sarcoma should be followed up. The purpose of this study was to determine current practice in the United Kingdom. 192
clinicians treating patients with soft tissue sarcoma were surveyed with a postal questionnaire enquiring about frequency and
method of follow up and how patients would be followed up in each of 3 clinical scenarios: a patient with a trunk or extrem-
ity tumour at low risk of relapse; a patient with a trunk or extremity tumour at high risk of relapse; and a patient with a
retroperitoneal or abdominal tumour. 155 (81%) clinicians responded. Clinic visits and X-rays were the most frequently used
methods of follow up. Chest CT scans, local site imaging, and blood tests were used infrequently. The intensity and meth-
ods of follow up varied with each of the clinical scenarios. There was a seven-to-twenty fold variation in cost between the
least and the most expensive regimes. Respondents were generally supportive of the development of the clinical trial in this
area.
Copyright © 2007 C. H. Gerrand et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Soft tissue sarcomas are a heterogenous group of rare tu-
mours of mesenchymalorneuroectodermal origin. Theycan
occur in any anatomical location, with around 55% in the
trunk or extremities, 35% in the retroperitoneum or viscera,
and10%intheheadandneck(Pollocketal.[1]).Surgicalex-
cisionwithorwithoutadjuvantradiotherapyisthetreatment
of choice for localised disease (Yang et al.[2]). The role of ad-
juvant chemotherapy remains unproven (Tierney et al.[3]).
There is a signiﬁcant rate of relapse following primary treat-
ment, with 10-year local recurrence rate of 10–20% and 10-
year disease-speciﬁc survival rate of 50–60% in published se-
ries (Eilber et al.[4]; Kattan et al.[5]; Trovik [6]). Retroperi-
toneal tumours are associated with poorer disease-speciﬁc
survival than tumours in the extremity (Kattan et al.[5]).
Prognostic factors for tumour relapse are well documented
but complex, as diﬀerent factors contribute to the risk of lo-
cal and distant recurrence. Despite evidence that some pa-
tients who relapse can be salvaged, and that diﬀerent follow-
up practices may aﬀect patient outcome and have signiﬁcant
ﬁnancial implications, few studies have looked at how pa-
tients with soft tissue sarcoma should be followed up.
As u r v e yo fm e m b e r so ft h eS o c i e t yo fS u r g i c a lO n c o l -
ogy (Ill, USA) demonstrated signiﬁcant variation in follow-
up protocols after treatment of soft tissue sarcoma (Beitier
et al.[7]). The estimated costs of follow up were shown to
vary between protocols by a factor of 43 (Goel et al.[8]).
However, little is known about current practice in the United
Kingdom, where most cancer care is delivered within the Na-
tional Health Service. A survey of UK clinicians was under-
taken to determine how patients with soft tissue sarcoma are
followed up in the United Kingdom. This paper reports the
results from this survey, which will inform the development
of guidelines about follow up and further clinical studies in
this area.2 Sarcoma
2. MATERIALS AND METHODS
A cross-sectional survey was carried out in 2004 on be-
half of the National Cancer Research Institute (NCRI) Sar-
coma Clinical Studies Group. The target population com-
prised clinicians treating patients with soft tissue sarcoma
in the United Kingdom. There is no deﬁnitive list of these
clinicians available, and therefore a list was compiled from
records held by the British Sarcoma Group, the Sarcoma-UK
supportgroup,andaweb-baseddirectoryofhospitalspecial-
ists (www.specialistinfo.com). Theauthorsreviewedtheﬁnal
list for errors or omissions.
The survey instrument was a self-completed question-
naire administered by post. It was based on, but not iden-
tical to the survey performed by Johnson et al., (Beitier et al.
[7]; Johnson et al.[9]; Sakata et al. [10, 11]). The question-
naire comprised 31 items in three sections. The ﬁrst sec-
tion contained items asking about the clinical practice and
specialty interests of respondents. The second section asked
about the follow-up practices of respondents and requested
speciﬁc information about how patients in three clinical sce-
narioswouldbefollowedup.Thesescenarioswereasfollows:
a patient with a trunk or extremity tumour at low risk of re-
lapse; a patient with a trunk or extremity tumour at high
risk of relapse; and a patient with a retroperitoneal or in-
traabdominal tumour. Questions included the overall length
of follow up, the number of outpatient visits, chest x-rays,
chest CT scans, and local site imaging investigations (USS,
CT, or MRI) performed in each of the ﬁrst 5 years of follow
up and in each year thereafter. In the third section, respon-
dents were asked about their motivation for following pa-
tients up and about opinions of a proposed study of follow-
up protocols.
Before distribution, the questionnaire was piloted infor-
mally amongst a small group of clinicians. To maximise the
response rate, the initial mailing included a single question-
naire with covering letter and a stamped addressed envelope.
Reminder letters were sent at two, four, and six weeks, with a
replacement questionnaire at four weeks. Some nonrespon-
ders were also contacted by email or telephone.
2.1. Costanalysis
For each of the three diﬀerent clinical scenarios, the re-
sponses given by each clinician for number of outpatient vis-
its, chest x-rays, chest CT scans, and local site imaging inves-
tigations during follow up were multiplied by unit costs for
these resource usage items to give a total cost for follow up. It
was assumed that patients followed to “adulthood” or “life-
long” were followed for a total of 10 years, and the patient
survived to the end of the maximum follow up period and
that local site imaging, where used, was an MRI scan. The
cost of blood tests was not included, and the costs of treat-
ment of a detected relapse were not considered. Unit costs
were taken from the Department of Health National Refer-
enceCostIndex(Health[12])(London,UK)andwerecosted
at £62 for an outpatient visit, £87 for a chest x-ray, £179 for a
chest CT scan, and £285 for an MRI.
3. RESULTS
3.1. Responseratetosurvey
A list of 192 names from 45 diﬀerent centres was compiled.
Questionnaires were returned by 155 of those originally sur-
veyed, giving an overall response rate of 81%. Of these 155,
twenty-one respondents were not involved in the treatment
of soft tissue sarcomas, three had retired, three could not be
traced, and seven were returned blank leaving 121 question-
naires from 43 diﬀerent centres available for analysis. These
are referred to as the survey respondents.
3.2. Characteristicsandpracticeof
surveyrespondents
Of the 121 survey respondents, 32 were clinical oncologists,
30 orthopaedic surgeons, 26 paediatric oncologists, 16 med-
ical oncologists, 11 general surgeons, and 6 were plastic sur-
geons. There were 119 consultants, one staﬀ grade, and one
registrar. Within the survey respondents, 74 (61%) declared
membership of at least one specialist society related to the
treatment of sarcomas.
Management of patients with soft tissue sarcoma formed
more than 50% of clinical workload in 13 (11%) survey re-
spondents, between 11% and 50% of clinical workload in 53
(44%) and less than 10% of clinical workload in 54 (45%) (1
not speciﬁed). The majority of the survey responders (110;
91%) were responsible for the long-term follow up of pa-
tients with soft tissue sarcoma and most (110; 91%) had ac-
cess to a multidisciplinary team dealing with sarcomas.
3.3. Perceivedriskfactorsforrelapse
Seventy-ﬁve of 100 responders (75%) stated their follow-up
protocolforadultpatientswithsofttissuesarcomadepended
upon the perceived risk of local or systemic relapse (21 did
not answer this question due to lack of involvement either in
long-term follow up or in adult patients). Responders were
asked which of a choice of factors (histological grade, un-
planned excision before referral, tumour size, surgical mar-
gins, age over 50 years, deep location, histological type) they
considered signiﬁcantly increased the risk of local recurrence
andmetastaticdiseaseinpatientswithsofttissuesarcoma.Of
the 107 respondents who answered this question (14 nonre-
sponders due to lack of involvement either in long-term fol-
low up or in adult patients), surgical margin status (96%),
histological grade (89%), and tumour size (87%) were the
three most commonly chosen risk factors for local recur-
rence, whereas histological grade (94%), tumour size (83%),
and histological type (77%) were the three most commonly
chosen risk factors for metastatic disease. In both cases, age
over 50 years was lowest in popularity as a risk factor (14%
for local recurrence and 13% for metastatic disease). Other
risk factors mentioned included site of disease, previous re-
currence at site, adjuvant therapy, and genetics.C. H. Gerrand et al. 3
Table 1: Length of follow up after treatment.
Low risk trunk or High risk trunk or Abdominal or
extremity tumours extremity tumours retroperitoneal
(N = 88) (N = 99) tumours (N = 63)
Less than 5 years 3 (3%) 0 (0%) 1 (2%)
Exactly 5 years 39 (44%) 22 (22%) 12 (19%)
At least 5 years 7 (8%) 9 (9%) 6 (10%)
Exactly 8 years 1 (1%) 2 (2%) 2 (3%)
Exactly 10 years 20 (23%) 36 (36%) 24 (38%)
At least 10 years 6 (7%) 6 (6%) 4 (6%)
At least 15 years 0 (0%) 1 (1%) 0 (0%)
U n t i la d u l t h o o d 1( 1 % ) 2( 2 % ) 1( 2 % )
Lifelong 9 (10%) 15 (15%) 10 (16%)
No response 2 (2%) 6 (6%) 3 (5%)
Table 2: Number of clinic visits per year after treatment by clinical scenario.
Median (range) number of clinic visits per year after treatment
Clinical scenario Year 1 Year 2 Year 3 Year 4 Year 5 Each year thereafter
Low-risk trunk or extremity tumours 4 (1–12) 3 (1–6) 2 (1–6) 2 (1–6) 1 (1–6) 1 (0–2)
High-risk trunk or extremity tumours 4 (2–12) 4 (1–6) 2 (1–4) 2 (1–6) 2 (1–6) 1 (0–2)
Abdominal or retroperitoneal tumours 4 (2–12) 4 (1–6) 2 (1–6) 2 (1–6) 2 (0–6) 1 (0–2)
3.4. Actualfollow-uppracticefordifferent
clinicalscenarios
The second part of the questionnaire related to three dif-
ferent clinical scenarios. Because of variation in the patients
treated by survey respondents, 88 were able to answer ques-
tions about the follow up of patients with trunk or extremity
tumours at low risk of relapse, 99 about patients with high-
risk trunk or extremity tumours, and 63 about patients with
retroperitoneal or intra-abdominal tumours. Length of fol-
low up varied with the clinical scenarios described (Table 1).
For patients with trunk or extremity tumours at low risk of
relapse, answers ranged from 1 year to lifelong with 5 years
the most common response (44%) and 10 years the second
most common (23%). For those with trunk or extremity tu-
mours at high-risk answers ranged from 5 years to lifelong
with 10 years the most common response (36%) and 5 years
less common (22%). Responses for patients with retroperi-
toneal or abdominal tumours were similar to the high-risk
responses, with answers ranging from 4 years to lifelong, 10
years the most common response (38%) and 5 years second
most common (19%).
Clinic visits and chest X-rays were the most common
methods forfollowup.Thefrequencyofclinicvisitsdeclined
with time (Table 2). The most common pattern for patients
with low-risk trunk or extremity tumours in the ﬁrst 5 years
was 4 visits in years 1 and 2 and 2 visits in years 3, 4, and 5
(14%; 12/88). This pattern was also the most frequent for
patients with high-risk trunk or extremity tumours (18%;
19/99) and retroperitoneal/abdominal tumours (13%; 8/63).
The median total number of clinic visits in 5 years was 12 (5
to 30) for low-risk trunk or extremity tumours, 14 (6 to 27)
for high risk trunk and extremity tumours and 14 (5 to 30)
for retroperitoneal or abdominal tumours.
The use of radiological investigations and routine blood
tests for follow up is summarised in Table 3. All investiga-
tionswereusedmoreoftenforhigh-riskcomparedwithlow-
risk trunk or extremity tumours. There was wide variation
in the use of these investigations. Most respondents (>85%)
speciﬁed the use of at least one chest x-ray during follow
up but responses ranged from no chest x-rays requested to
as many as 24 in the ﬁrst 5 years of follow up. Chest CT
scans were used less frequently for follow up, being used in
16% of low-risk trunk or extremity tumours, 29% of high-
risk trunk or extremity tumours and 25% of abdominal or
retroperitoneal tumours. Local imaging investigations were
used for follow up for just 38% of patients with low-risk tu-
mours but 61% of patients with high-risk and 73% of pa-
tients with abdominal or retroperitoneal tumours. Few re-
spondents (<10%) routinely used blood tests in follow up.
3.5. Attitudestofollowup
Of the 121 survey respondents, 106 completed questions on
attitudes to follow up with the remaining 15 not respond-
ing, possibly due to lack of involvement either in follow up
or in adult patients. Despite the variation in practice, 88/106
(83%) of respondents thought that regular follow up was of
beneﬁt for patients with soft tissue sarcoma, with only 3 stat-
ing that they did not think it was of beneﬁt and the remain-
ing 15 not sure. Forty (38%) believed that detecting metas-
tases before they become symptomatic leads to improved
survival for patients, with 45 (42%) not sure. Seventy-one
(67%) thought that detecting a local recurrence before it be-4 Sarcoma
Table 3: The use of radiological investigations or blood tests for follow up.
Chest x-rays Chest CT scans Local imaging
Routine
blood
tests Clinical scenario At least one Median number
in 5 years (range) At least one
Median num-
ber in 5 years
(range)∗
At least one
Median num-
ber in 5 years
(range)∗
Low-risk trunk or
extremity tumours
76/88 (86%) 8 (0–24) 14/88 (16%) 0 (0–6) 33/88 (38%) 1 (0–13) 5/88 (6%)
(5 no response) (15 no response) (13 no response)
High risk trunk or
extremity tumours
90/99 (91%) 13 (0–24) 29/99 (29%) 0 (0–10) 60/99 (61%) 2 (0–13) 8/99 (8%)
(8 no response) (15 no response) (12 no response)
Abdominal or 55/63 (87%) 12 (0–24) 16/63 (25%) 0 (0–9) 46/63 (73%) 5 (0–13) 6/63 (10%)
retroperitoneal
tumours (6 no response) (10 no response) (7 no response)
∗Some respondents speciﬁed that CT scans and local imaging should only be performed when clinically indicated rather than routinely.
came symptomatic was of beneﬁt to patients, with 26 (25%)
not sure.
This ﬁnal part of this section also asked the respon-
dents their opinion about carrying out a randomised trial of
follow-up protocols in adult patients who have been treated
for soft tissue sarcoma possibly with randomisation accord-
ing to the risk of relapse. Of 106 survey respondents, 96
(91%) felt a trial of this kind to be worth taking forward
with 85 (80%) prepared to enter patients into such a trial.
In terms of follow-up protocols, at the one extreme 53/106
(50%)wouldnothaveaproblemwithanintensivefollow-up
regime involving regular chest CT and/or local site imaging
and at the other extreme 57/106 (54%) thought it would be
reasonable to follow up selected patients in the community.
3.6. Estimatedvariationincosts
The mean costs of the stated practice for follow up for low-
risk trunk or extremity tumours was £2,542 (£372 to £7,852;
n = 64),forhigh-risktrunkorextremitytumourswas£3,548
(£1,091 to £7,961; n = 83), and for retroperitoneal and ab-
dominal tumours was £3,876 (£595 to £7,961; n = 45).
4. DISCUSSION
This paper has identiﬁed for the ﬁrst time how patients
with soft tissue sarcoma are followed up after treatment in
the United Kingdom. We undertook a questionnaire survey
of hospital clinicians with a declared interest in the man-
agement of sarcomas. In the past decade, there has been a
move to manage all malignancies through regionally accred-
ited multidisciplinary teams (MDT). Sarcoma services have
lagged behind the more common solid tumours in this pro-
cess, so patients with soft tissue sarcomas are often treated
by nonspecialist orthopaedic, plastic, or general surgeons
(Clasby et al.[13]; Glencross et al.[14]). Our survey included
only those with a declared interest in sarcoma, of whom 91%
had access to an MDT. This, therefore, represents best prac-
tice in the UK, and likely excludes those units where sarco-
mas are treated by generalists. Any questionnaire survey has
the potential weakness of nonresponse bias but the response
rate in our study was high and the level of completeness was
good. Therefore, we believe the results are representative of
UK clinicians involved in follow up for sarcoma.
We have shown that most clinicians follow up their pa-
tients, most frequently with clinic visits and chest x-rays.
Chest CT scanning and local site imaging, such as MRI or
CT, are used less frequently; and blood tests seldom used. As
expected, the frequency of clinic visits and investigations de-
clines with time but we have shown considerable variation in
practice,andthereforeinthecostoffollowup.Ourstudywas
not designed to look at the diﬀerences in follow-up practices
between diﬀerent medical specialties.
Follow up after treatment of a malignant tumour serves
a number of purposes. The major goal is the detection of lo-
cal or systemic recurrence of disease, but other goals include
the reassurance of patients, the collection of data about out-
comes, management of the late eﬀects of treatment, and the
detection of second malignancies or other unrelated medi-
calconditions(Brennan[15]).Althoughfollow-upprotocols
may be driven by the concept that early physician-lead detec-
tion of recurrence leads to improved survival, there is little
evidence for this (Brennan [15]). Our respondents reﬂected
this uncertainty. Although the majority felt that follow up
was of beneﬁt after treatment of soft tissue sarcoma, there
was less certainty about whether or not early detection of lo-
cal recurrence or asymptomatic chest metastases beneﬁts pa-
tients.
The clinician’s choice of follow-up protocol is likely to
be inﬂuenced by factors such as training, age, the availabil-
ity of clinic time, and whether or not there are appropriate
treatmentsforrelapsedpatients(Sakataetal.[10]).Ourstudy
conﬁrms that clinicians in the United Kingdom also vary fol-
low up according to the perceived risk of relapse, which is
similar to the results of the survey by the American Society
of Surgical Oncology (Sakata et al.[11]). Respondents were
asked to state which factors they associated with disease re-
lapse. In our survey, the three factors most often selected by
respondents as associated with local recurrence were surgi-
cal margin status, histological grade, and tumour size. Pub-
lished series support surgical margin status and histological
grade as predictors of local recurrence; there is less support
for tumour size as a predictor (Coindre et al.[16]; Pisters
et al.[17]; Stojadinovic et al.[18]; Trovik et al.[19]).C. H. Gerrand et al. 5
Respondents selected histological grade, tumour size,
and histological type most often as risk factors for metastatic
disease. The literature supports the view that the main risk
factors for metastatic disease and overall survival are tumour
grade,size,anddepthwithsomeinﬂuencealsooftumourdi-
agnosis,site,andpatientage.Thishasbeenincorporatedinto
anomogram,whichisalsoavailableonline(Kattanetal.[5]).
Follow up is expensive; variation in protocols results in
signiﬁcant variation in costs. Although our cost model is
somewhat simplistic and does not account for the cost of
treatment of relapse or allow for drop out because of death,
it shows a seven-to-twenty fold diﬀerence in follow-up costs
betweenthemostandtheleastintensiveregimensdepending
on the type of clinical scenario. This is less extreme than the
experience in the United States where a 42.8-fold variation in
cost was identiﬁed ($485–$21,235; mean cost $6,401) (Goel
et al.[8]) but still is indicative of the large eﬀect on cost that
results from wide variability in practice. It is likely that many
of these follow-up regimes are not cost eﬀective.
Patients are good at detecting local recurrences of tu-
mours in the trunk and extremity; most local recurrences are
detected either by the patient or their primary care physician
between clinic visits (Kattan et al.[5]; Whooley et al.[20]).
Local site imaging is a low-yield investigation, detecting only
one of 29 local recurrences in a series in which selected pa-
tients with high-grade tumours received local site imaging
annually (Whooley et al.[20]). The impact of regular local
site imaging for all patients is not known, but might be ex-
pected to lead to earlier detection of local recurrence in some
patients at the expense of a number of false-positive scans in
others.
Following detection of locally recurrent soft tissue sar-
coma in the extremities or trunk, adequate local therapy can
lead to prolonged survival (Moureau-Zabotto et al.[21]; Tro-
vik [6]), although these patients are at increased risk of sys-
temic relapse (Ramanathan et al.[22]). Complete resection
of the local recurrence is an important part of this treatment,
but whether regular surveillance increases the likelihood of
success in this regard is not clear. Treatment of a local recur-
rence is more likely to require amputation compared with
treatmentof a primary tumour (Trovik[6]) and it is possible
that early detection of local recurrence might prevent this in
a number of cases or could lead to improved function of the
salvaged extremity. Adjuvant radiotherapy is recommended
following subablative resection of locally recurrent disease,
but this too can result in long-term impairment of function.
Local recurrences of tumours in the retroperitoneum
or abdomen are more diﬃcult to detect clinically and our
survey conﬁrms that local imaging is more widely used in
this setting. Salvaging patients with locally recurrent tu-
mours in these anatomical sites is diﬃcult, although some
patients with low-grade tumours can have repeated debulk-
ing surgeryover several years. Once more, the value of earlier
detection in this situation has not been determined.
Screening for asymptomatic lung metastases is contro-
versial.Inoursurvey,chestX-rayswereusedmorefrequently
than chest CT scans for the detection of metastases. The for-
mer are cheaper and can be done in the clinic. The use of
chest CT scans might be expected to lead to the earlier de-
tection of metastases, but is associated with greater radiation
exposure to patients. There is evidence that a signiﬁcant pro-
portion of patients with metastases can achieve long-term
survival with appropriate treatment (van Geel et al.[23]). In
one study, 248 of 719 patients presenting with pulmonary
metastases underwent surgical resection (Weiser et al.[24]).
These patients remain at risk of further relapse, but even sec-
ond and third relapses can, on occasion be treated success-
fully (Weiser et al.[24]). Much seems to depend on whether
or not the metastases can be completely removed at the
time of surgery; patients with unresectable metastases are
incurable (Billingsley et al.[25]; Casson et al.[26]; van Geel
etal.[23]).Given thelackofrandomised studies, thereareno
data to indicate a survival advantage for metastectomy. Pa-
tients most likely to be salvaged after developing lung metas-
tases are younger, have a grade one or two primary tumour,
and present with a solitary metastases after a long disease-
free interval and which can be widely resected (Billingsley
et al.[25]; van Geel et al.[23]). Cytotoxic chemotherapy is
eﬀective for some (objective response rates less than 20%)
but the median survival is only 12 months (van Glabbeke
et al.[27]).
The variation in practice and cost shown in this survey
suggest a role for a randomised study to determine the op-
timum strategy for follow up of this group of patients. Such
a study should consider the economic cost of follow up, the
psychological impact on the patient, and whether more in-
tensive regimes lead to earlier detection of local or systemic
disease than less intensive regimes. Such a study might also
investigate the most eﬀective imaging modalities for detec-
tion of local or systemic disease and the impact of patient ed-
ucationprograms.Theimpactofearlierdetectionand,there-
fore, treatment on overall survival and on the function or
preservation of an extremity after treatment for local recur-
rence should also be considered. Resolving these questions
into a single study may be challenging.
5. CONCLUSION
This study has deﬁned for the ﬁrst time how patients who
have been treated for soft tissue sarcoma in the United King-
dom are followed up after treatment. We have demonstrated
that there is wide variation in practice and cost. Follow up
is clearly a question of balancing a number of objectives,
including maximising survival, quality of life, psychological
outcomes,andfunction.Giventhatthereislittleevidencefor
one follow up protocol over another, there is clearly potential
fordevelopingastudyoftheseissuesintheUnitedKingdom.
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